Innovate UK

Z-PULSE, a spin-off from the University of Surrey, creates wearable health sensors that run on their own power.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

The goal of Reneural is to use technology to revolutionize healthcare delivery by increasing its effectiveness, efficiency, and accessibility for both patients and physicians.

Myogenes provides psychiatric tests, heredity cancer tests, and mental health mind maps.

Kaydiar is a medical device company focused on developing innovative, cost-effective solutions for wound care, particularly for pressure injuries. They specialize in offloading technology, creating products such as orthotic devices, bed mattresses, wheelchair cushions, and prosthetic sleeves to relieve pressure and promote healing.

Naitive is a population health company focused on improving patient care through AI-enabled clinical pathways and medical device technology. The company develops software that employs artificial intelligence, clinical data, and digital interventions to enhance the identification, treatment, and coordination of care for chronic diseases. By leveraging advanced computational capabilities, Naitive aims to support clinicians in transforming patient care while simultaneously reducing costs, time, and the failure rates commonly associated with chronic disease management.

Fuse Diagnostics focuses on manufacturing diagnostic products that deliver lab-quality information across various sectors. The company aims to provide innovative and cost-effective testing solutions that ensure laboratory accuracy for applications in food and water testing, bioprocessing, and cell biology research. By offering low-cost test kits equipped with integrated readout technology, Fuse Diagnostics enables businesses to obtain rapid and reliable results, thereby enhancing the accessibility and efficiency of diagnostic testing.

Medicsen is a start-up focused on healthcare innovation, primarily through the development of advanced technology solutions. A notable project is GlycSen, a needle-free drug delivery device aimed at providing a painless treatment option for individuals with insulin-dependent diabetes. This device integrates data from continuous glucose meters and user-inputted information, utilizing a learning algorithm to facilitate real-time monitoring. It features a chatbot interface that allows patients to easily track their condition, enhancing their ability to manage diabetes effectively. Through these innovations, Medicsen aims to improve the quality of life for those living with chronic diseases.

Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.

Occuity Ltd is a company based in Reading, United Kingdom, that focuses on the research, design, and manufacture of non-contact optical instruments for healthcare diagnostics and monitoring. Founded in 2019, it offers a range of handheld devices, including pachymeters, pupillometers, and keratometers, which are utilized in both human and veterinary optometry. These instruments employ light to analyze the eye, facilitating direct measurements that assist optometrists and ophthalmologists in diagnosing and monitoring various health conditions, such as diabetes and Alzheimer's disease. By providing innovative non-contact solutions, Occuity aims to enhance the effectiveness and accessibility of diagnostic and screening technologies in the healthcare sector.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

PulmoBiomed is a developer of innovative sampling technology that offers a non-invasive method for clinicians and researchers to collect biological samples. The company's primary product is a passive fluid aerosol sampler designed to capture exhaled breath condensate and environmental particles, effectively segregating them by size. This technology addresses critical challenges in sample collection, such as preventing contamination and loss, while ensuring the generation of highly reproducible data with digital molecular precision. By focusing on metabolomic profiling and biological agent capture, PulmoBiomed aims to enhance the accuracy and reliability of respiratory diagnostics and research.

Lucida Medical is a developer of healthcare technology that utilizes artificial intelligence to enhance the detection and diagnosis of cancer. The company has created software that supports the analysis of MRI scans, focusing on applications for cancer diagnosis, screening, and management. Its flagship product, Pi, is designed specifically for the diagnosis of prostate cancer through multiparametric or diffusion MRI and has received CE marking as a medical device. By integrating imaging and multi-omics biomarkers, Lucida Medical aims to provide clinicians with tools that make cancer detection more accurate, accessible, cost-effective, and rapid. The company is interested in collaborating with investors and hospital partners who share its commitment to early cancer detection.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Holly Health is a digital health coaching application that assists individuals in transforming their health intentions into actionable daily habits for improved mental and physical wellbeing. Utilizing proprietary AI systems, the service mimics the support of a human health coach, offering personalized guidance to users. The application features tools such as habit reminders, tailored health content, and progress tracking, all aimed at helping users establish and maintain healthier routines. Recognized as one of the top health apps for weight management, stress reduction, wellness, and sleep, Holly Health achieved a notable evaluation score of 89% from ORCHA, a leading health app assessment organization. Launched internationally in Summer 2021, the company aims to support five million individuals by 2025 and is actively partnering with primary care practices in the UK, having established over 100 collaborations to date.

Holly Health is a digital health coaching application that assists individuals in transforming their health intentions into actionable daily habits for improved mental and physical wellbeing. Utilizing proprietary AI systems, the service mimics the support of a human health coach, offering personalized guidance to users. The application features tools such as habit reminders, tailored health content, and progress tracking, all aimed at helping users establish and maintain healthier routines. Recognized as one of the top health apps for weight management, stress reduction, wellness, and sleep, Holly Health achieved a notable evaluation score of 89% from ORCHA, a leading health app assessment organization. Launched internationally in Summer 2021, the company aims to support five million individuals by 2025 and is actively partnering with primary care practices in the UK, having established over 100 collaborations to date.

At Holly Health, we are transforming the way individuals approach mental and physical well-being. Founded in 2020, we’ve developed an AI-powered digital health coach that empowers users to turn their health intentions into clear, actionable steps. Our personalized, compassionate service is designed to fit seamlessly into everyday life, supporting long-term, sustainable health changes. Using proprietary AI systems, Holly Health mimics the guidance of a human health coach, offering support in areas such as weight management, stress reduction, wellness, and sleep. We are proud to be ranked among the top 3 health apps by ORCHA, the world’s leading health app evaluation body, with a score of 89%. Since our international launch in 2021, Holly Health has been on a mission to improve the lives of 5 million people by 2025. We are rolling out partnerships with over 100 primary care practices in the UK, helping healthcare professionals support patients with preventative health measures and ongoing well-being. At Holly Health, we believe that health is not a destination but a journey. By offering tailored, science-backed coaching, we make it easier for people to prioritize their well-being every day. Join us as we revolutionize digital health coaching for the modern world.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Kalium Health Ltd is a company focused on improving kidney care through innovative medical technology. Based in Cambridge, United Kingdom, it designs and manufactures a finger-prick blood test specifically for measuring blood potassium concentration. This test aims to facilitate early treatment for patients, reducing the complications and costs associated with traditional testing methods. By leveraging advanced electrolyte sensing technology, Kalium Health provides patients with accurate, real-time data essential for managing cardiorenal diseases. The company’s first product addresses a significant risk in kidney disease, a condition that imposes substantial financial burdens on healthcare systems. With a clear regulatory pathway and a targeted market strategy, Kalium Health is poised to transform patient care and enhance outcomes for millions affected by kidney disease.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Kids Speech Labs is a digital health company focused on transforming the delivery of speech and language therapy services through innovative technology. The company develops AI-driven solutions that include remote monitoring tools and interactive speech and language games. These resources empower parents to track their children's speech development effectively. By leveraging artificial intelligence, Kids Speech Labs aims to enhance the therapeutic experience, making it more accessible and engaging for children and their families.

GG Care helps care residents stay independent and help carers monitor their well-being, comfort, and mood. They serve people with dementia maintain daily routines and stay socially connections shown to reduce cognitive decline and increase happiness and creates an environment to help reduce agitation - significantly reducing the cost of care.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

Tycho Medlink is to help people achieve new levels of rehabilitation through digital therapy.

Nanovery Limited, founded in 2018 and based in London, United Kingdom, specializes in developing nanorobots aimed at detecting cancer mutations. The company's innovative platform utilizes artificial intelligence to facilitate the rapid and ultra-sensitive identification of challenging biomarkers in blood samples. These nanorobots can capture circulating tumor DNA and emit a fluorescent signal, enabling healthcare professionals to conduct point-of-care tests. By facilitating early cancer detection, Nanovery aims to enhance patient outcomes and increase survival rates. The organization is supported by a team of experts in nanotechnology, medicinal chemistry, and artificial intelligence, along with backing from leading academics, clinicians, and industry leaders.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Its technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

Emm is focused on creating innovative consumer health tools that empower individuals to manage their health effectively. The company has developed a wearable device aimed at enhancing reproductive health by providing users with biometric data that offers actionable insights into their unique reproductive profiles. This technology enables users and their healthcare providers to identify potential health issues and optimize reproductive health outcomes, thereby improving the overall quality of life. Emm's approach combines advanced technology with specialized knowledge to enhance personal health management.

Vann is a platform for people affected by cancer aiming to help millions of people globally and revolutionize cancer research and care. Vann has been backed by the Oxford University Innovation, Innovate UK, OxLEP European Regional Development Fund, and UK angel investors and is based in the UK.

eMoodie is a technology company that has developed an app designed for ecological momentary assessment research, focusing on mental health, emotions, and socialization patterns in children and adolescents. The app, designed as a research tool, examines symptoms, feelings, and health aspects, including sleep, in older kids, teenagers, and adults. It also enables parents to monitor and mitigate the digital mental impact on their children.

iEthico is a company focused on resolving drug supply and shortage issues through a digital supply chain platform. This platform streamlines the sourcing of medicines by providing automated, cloud-based services that track data and generate essential insights. It alerts users to potential shortages and connects pharmacists with reliable suppliers, thereby empowering them to manage their inventory effectively. The service features an MHRA-approved automated regulatory process that minimizes paperwork, saving time for pharmacies. Following successful market testing, iEthico's solution is currently being rolled out to community pharmacies and NHS Trusts across the UK, aiming to enhance the efficiency of medicine distribution and reduce costs for healthcare providers.

Drill Surgeries is a technology company specializing in AI-powered surgical navigation systems for trauma and orthopedic procedures. Their proprietary AI algorithms and mixed reality technologies aim to significantly reduce operating room time and enhance surgical precision, thereby minimizing failure rates and unnecessary radiation exposure. By doing so, they help hospitals save substantial costs per operation.

Acurable Limited is a MedTech start-up based in London that specializes in the design and commercialization of a wearable sensor-based health care device aimed at diagnosing and managing respiratory conditions in a non-invasive manner. The company's flagship product, AcuPebble, allows for the diagnosis of sleep apnea and the monitoring of various respiratory and cardiac conditions through advanced algorithms that analyze acoustic signals. This technology, which emerged from a decade of research at Imperial College London, provides more accurate readings than existing solutions, significantly reducing the risk of misdiagnosis. AcuPebble is designed for home use, requiring no specialist training, which helps lower healthcare costs. Acurable's mission is to gain a comprehensive understanding of human biosignals to ensure that treatable conditions do not result in preventable deaths.

ProtonDx is a diagnostic platform that specializes in molecular testing services, focusing on the rapid and precise detection of multiple pathogens from samples. The company develops point-of-care diagnostic test devices aimed at assisting healthcare professionals in diagnosing infectious diseases. Utilizing innovative microchip technology, ProtonDx integrates molecular biology with machine learning, allowing for swift deployment in clinical settings. This enables healthcare organizations to efficiently manage infected patients and monitor pandemic situations in real-time. ProtonDx emphasizes speed, sensitivity, specificity, and convenience in its offerings, positioning itself as a vital resource for frontline healthcare staff.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Medwise.ai offers a customizable search platform designed to support clinical decision-making for healthcare professionals. Utilizing natural language processing and artificial intelligence, the platform enables doctors to efficiently access and organize medical knowledge. By leveraging real-world data, Medwise.ai provides valuable intelligence and insights to various stakeholders within the healthcare ecosystem. This innovative approach aims to enhance the professional capabilities of doctors, ultimately improving patient care and outcomes.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Invatech Health provides software as a service solution. It also develops several products to address unresolved issues in areas such as domiciliary care and mental health. It specializes in the healthcare and social care industries.

Lumino is focused on enhancing mental health outcomes through the development of digital therapeutic programs. These programs specifically address various mental health concerns and incorporate techniques such as cognitive behavioral therapy (CBT) to help individuals manage their symptoms effectively. Supported by Innovate UK and the Oxford Academic Health Science Network, Lumino aims to leverage digital technology to deliver scalable mental health services, ultimately promoting healthier and happier lives for users.

Decorte Future Industries is a venture-backed startup focused on utilizing artificial intelligence to extract health data from sound. The company has developed advanced machine-learning methods that enable the extraction of complex biometrics, including cardiovascular and respiratory health, from audio recorded via standard microphones. This innovative approach allows clients to gather intricate health data efficiently and at scale, simplifying the process of health monitoring.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.

Liopa Ltd, established in 2015 and based in Belfast, UK, specializes in biometric authentication and verification technology. The company's flagship product, LipVerify, uses advanced machine learning and AI to analyze lip movements and validate a user's identity. Liopa's innovative Visual Speech Recognition (VSR) technology, first commercialized through the SRAVI app, enables individuals who have lost their ability to speak to communicate by deciphering lip movements. This technology is currently being trialed in NHS Intensive Care units.

Medwise.ai offers a customizable search platform designed to support clinical decision-making for healthcare professionals. Utilizing natural language processing and artificial intelligence, the platform enables doctors to efficiently access and organize medical knowledge. By leveraging real-world data, Medwise.ai provides valuable intelligence and insights to various stakeholders within the healthcare ecosystem. This innovative approach aims to enhance the professional capabilities of doctors, ultimately improving patient care and outcomes.

ONKO is a provider of unified cancer care. ONKO combines digital technology with the support of healthcare professionals to provide patients with personalised expertise from cancer dietitians, physiotherapists, specialist nurses and psychologists.

Thomson Screening is a supplier of software for health needs assessments, immunisations, and health screening. They offer schoolscreener software for managing and automating health program requirements. They also provide workscreener platform to provide critical health information to employers across sectors, such as the private sector and the public sector.

Game Doctor develops data-driven gamification technology. They offer services that include big data, mobile applications, health promotion, health marketing, public health, engagement, and behavior change.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

Appt is making preventive healthcare effortless and accessible. Appt uses behavioural economics and data analytics to increase the uptake of preventive healthcare appointments - earning practices additional income and helping the delivery of nationally set prevention targets. Furthermore, through end-to-end automation of the call and recall process, Appt reduces cumbersome practice workload saving practice staff valuable time.

Circada's unique lighting controls improve health and well-being. This consists of an adapter that connects to existing tuneable white LED drivers and is simple to retrofit without the need for complex commissioning, with a standard light switch serving as its interface. We can provide additional configuration prior to installation if necessary for a specific project in order to match the lighting specification, once again providing advanced circadian lighting that is plug-and-play and commission free.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.

Cognetivity Neurosciences Ltd., established in 2011 and based in Vancouver, Canada, operates as a healthcare technology company. It specializes in the development of an integrated cognitive assessment platform designed for use in medical and commercial settings. The platform aims to facilitate early diagnosis of dementia through AI-driven analysis of cognitive test results.

Gendius Ltd. is a company based in Macclesfield, United Kingdom, founded in 2011 by Chris Genders and Rory Cameron. It specializes in developing app-based solutions for individuals living with diabetes. The company's flagship product, Intellin, is an innovative platform that leverages a user’s clinical history to identify personal high-risk areas for diabetes-related complications. By focusing on these specific risks, Intellin guides users through clinically validated tasks and measures aimed at slowing the progression of their condition, thereby enhancing their quality of life and management of diabetes.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Healum is a developer of connected software and applications aimed at enhancing self-management for individuals with long-term health conditions. The company's AI-powered platform offers personalized care and support by leveraging data-driven insights and evidence-based behavioral interventions. Healum's tools enable patients to effectively monitor and understand both their physical and mental health, while also providing healthcare professionals with the means to assist patients in managing chronic conditions. This approach promotes a collaborative environment where patients receive customized support tailored to their unique health needs.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Concentric Health is a company focused on transforming health decision-making through its innovative e-consent application. The application enhances efficiency by addressing backlog issues and minimizing medico-legal risks through the use of trusted content. It aims to simplify complex processes for both patients and clinicians, fostering shared decision-making that is informed by patient outcomes. By providing a secure and auditable platform, Concentric Health improves the overall experience for users, ultimately leading to better health outcomes.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

BIOS Health is a pioneering company focused on developing neural digital therapies by leveraging data from the human nervous system. By identifying neural biomarkers that correlate nerve activity to specific medical conditions, BIOS aims to revolutionize precision medicine. Their research offers the potential for innovative treatments for a range of chronic diseases, including hypertension, diabetes, and neurodegenerative disorders such as Parkinson's and Alzheimer's. Co-founded by experts from Cambridge University, the team includes professionals from diverse fields such as neuroscience, machine learning, and biotechnology. Additionally, BIOS is working on prosthetic connectors that standardize connections between bionic devices and neural systems, facilitating neural control and feedback for amputees. This dual approach positions BIOS at the forefront of improving the quality of life for individuals with chronic conditions and those requiring prosthetic solutions.

Ieso Digital Health Ltd. is a provider of online, evidence-based mental health therapy, focusing on cognitive behavioral therapy (CBT) delivered through a digital platform. The company offers one-to-one therapy sessions for various mental health issues, including anxiety, depression, and phobias, as well as support for chronic physical health problems and cognitive impairments. Ieso's innovative approach combines proprietary technology with natural language processing and artificial intelligence to enhance therapy delivery through real-time monitoring and assessment. This enables therapists to provide effective care in a virtual environment, allowing patients to access support at their convenience. Serving a diverse clientele that includes health providers, private individuals, and businesses, Ieso aims to transform mental healthcare by making it more accessible and scalable. Founded in 2000 and based in Swavesey, United Kingdom, Ieso was previously known as PsychologyOnline.co.uk Limited before rebranding in 2015.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.

Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.

Mayden is a company that provides managed web applications and custom system development specifically for the healthcare sector. They focus on creating innovative, flexible, and cloud-based software solutions that enhance patient management, operational management, online service assessment, and secure hosting. By designing and supporting interoperable systems and platforms, Mayden aims to help healthcare providers deliver data-driven, outcome-focused, and patient-centered care. The company is based in the areas of Bath and Chippenham and employs 44 staff members, along with a network of skilled associates who contribute to specific projects. Mayden is committed to adding real value to healthcare by developing applications that transform service delivery for healthcare professionals and improve patient experiences.

Vitamica Ltd is a diagnostic technology company based in Bristol, United Kingdom, founded in 2018 as a spin-out from the University of Bristol. The company specializes in rapid antimicrobial susceptibility testing (AST) that determines the effectiveness of antibiotics against pathogenic bacteria. By utilizing advanced optical technology, Vitamica's diagnostic method detects nanoscale fluctuations in live bacteria, providing clinicians with crucial information to make informed decisions regarding antibiotic treatment. With an expanding intellectual property portfolio, Vitamica aims to capitalize on opportunities in the healthcare, veterinary, and pharmaceutical sectors, positioning itself as a notable innovator in the field of antimicrobial susceptibility testing.

PulmonIR is focused on the research and development of innovative medical devices aimed at detecting and monitoring lung diseases, particularly chronic obstructive pulmonary disease (COPD) and lung cancer. The company's technology is designed to assist healthcare professionals in diagnosing COPD patients more efficiently, allowing for quicker and safer treatment options for those suffering from these conditions. By streamlining the testing process, PulmonIR aims to improve patient outcomes and enhance the overall management of lung diseases.

Andiamo is a digital clinic focused on providing specialized care for neuromuscular conditions, starting with cerebral palsy. The company offers a custom medical wearables platform that allows families to connect with specialists conveniently and efficiently. By leveraging technology, Andiamo aims to improve access to healthcare resources and support for those affected by neuromuscular disorders, ensuring that families receive the necessary care when and where they need it.

MyWay Digital Health is an online self-management platform designed to enhance the lives of individuals with long-term health conditions, particularly diabetes. The platform offers users access to their health records, personalized advice, and educational resources, empowering them to take control of their health. Additionally, it provides tools for clinicians that support population analytics and decision-making, thereby facilitating improved health outcomes for users. Through its data-driven technology solutions, MyWay Digital Health aims to deliver comprehensive support for managing chronic conditions on a global scale.

Miotify Ltd. is a company based in Windsor, United Kingdom, that focuses on enhancing digital health applications through its software and online toolkit. Founded in 2015, Miotify enables both developers and non-IT personnel to create applications within a structured framework, ensuring quality is built into the process from the beginning. The platform facilitates the auto-generation of evidence necessary for regulatory submissions, thus streamlining compliance. Additionally, Miotify's algorithms transform data from devices and sensors, allowing for remote patient monitoring and providing valuable insights for clinical decision-making. The software supports medical practitioners and researchers by offering features such as iterations tracking, business case testing, and lifecycle management, which contribute to the safe and effective collection and analysis of clinical data.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.

Entia Ltd is a medical technology company based in London, United Kingdom, that focuses on enhancing access to blood tests through innovative healthcare devices. Founded in 2014, Entia offers two primary products: Aptus, a device for testing haemoglobin and haematocrit levels, and Affinity, designed for cancer patients to monitor their blood counts from home. These devices facilitate health screening, blood donor screening, maternal and child health, nutrition, and sports applications, while also enabling cancer patients to manage their health more effectively, reducing the risk of infection and minimizing hospital visits. The company employs a multidisciplinary team that encompasses design, engineering, quality assurance, and business development, all aimed at improving patients' quality of life by allowing them to conduct essential health monitoring from the comfort of their homes.

Arquer Diagnostics Ltd. specializes in the design, development, and commercialization of non-invasive diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in bodily fluids, including a CE-marked ELISA kit for Mcm5, which is utilized in hospital laboratories. Additionally, Arquer provides a point-of-care system that features a robust reader instrument and disposable cartridges, making it suitable for urology clinics, hospital laboratories, and general practitioners' surgeries. Founded in 2005 and based in Sunderland, United Kingdom, the company was previously known as UroSens Ltd. before rebranding in July 2015. Arquer’s patented technology allows for accurate and reliable detection of the MCM5 protein, aiding in cancer diagnosis and monitoring.

Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

DynamX Medical specializes in developing an innovative precancer screening system designed for rapid tissue biopsy analysis. This system is user-friendly and can be operated at the point of care by nurses, enhancing accessibility in clinical settings. The company's medical software aims to streamline the disease diagnosis process by increasing the speed and reliability of detection. This technology not only improves diagnostic efficiency but also helps healthcare institutions alleviate the strain on their resources. Through its advancements, DynamX Medical seeks to make significant contributions to early disease detection and patient care.

Isansys Lifecare is a digital healthcare company that has developed a patient status engine and a user-friendly, sophisticated patient monitoring platform. The PSE automates fundamental healthcare procedures. They focused on developing new patient-centered technology and data-driven methods in hospitals and healthcare organizations throughout the world.

Glyconics Ltd. is a diagnostics company based in Cambridge, United Kingdom, specializing in the development of portable infrared spectroscopy devices for the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Established in 2013, the company has created a hand-held device that utilizes Fourier transform infrared spectroscopy (FTIR) to analyze sputum samples for specific biomarkers associated with COPD. This innovative technology allows patients to perform diagnoses and monitor their health from home, facilitating early detection and management of respiratory diseases. By identifying particular spectral signatures in the samples, the device supports healthcare professionals in assessing and understanding patients' conditions more effectively.

Zilico Limited is a Manchester-based company focused on developing diagnostic devices aimed at improving cancer detection, particularly cervical cancer. Utilizing electrical impedance spectroscopy technology, Zilico's flagship product, ZedScan, operates alongside colposcopy to provide real-time, objective assessments of cervical epithelial tissue. This technology addresses the limitations of traditional diagnostic methods, which often involve subjective interpretations. Zilico is actively working on two applications: one targeting the referral market and another aimed at the screening market, both designed to enhance diagnostic accuracy and reduce the subjectivity associated with current practices. Since its founding in 2006, Zilico has aimed to deliver significant health economic benefits and improve cancer screening programs. The company was previously known as Aperio Diagnostics Limited before rebranding in 2008.